silo pharma inc. (nasdaq: silo), a developmental stage biopharmaceutical company, is focused on merging traditional therapeutics with psychedelic research for people suffering from indications such as post-traumatic stress disorder, fibromyalgia, alzheimer’s disease, parkinson’s disease, and other rare neurological disorders. silo’s mission is to identify assets to license and fund research that the company believes will be transformative to the wellbeing of patients and the health care industry. silo is committed to developing innovative solutions to address a variety of underserved conditions. combining silo’s resources with world-class medical research partners, the company looks to make significant advances in the medical and psychedelic space. silo works to identify and partner with leading medical universities, providing the needed financial resources to develop safe therapeutic treatments while moving cutting-edge research through the clinical stage and into commercialization.
Company profile
Ticker
SILO
Exchange
Employees
Incorporated
Location
Fiscal year end
Industry
Industry (SIC)
Former names
Gold Swap Inc, Point Capital, Inc., Uppercut Brands, Inc.
SEC CIK
Corporate docs
IRS number
273046338
SILO stock data
Latest filings (excl ownership)
8-K
Other Events
5 Apr 24
10-K
2023 FY
Annual report
25 Mar 24
8-K
Silo Pharma Announces Pipeline Prioritization for 2024 Targeting Mental Health, Chronic Pain, and Neurology
1 Feb 24
EFFECT
Notice of effectiveness
31 Jan 24
CORRESP
Correspondence with SEC
26 Jan 24
S-3/A
Shelf registration (amended)
25 Jan 24
UPLOAD
Letter from SEC
25 Jan 24
S-3
Shelf registration
23 Jan 24
8-K/A
Other Events
11 Jan 24
8-K
Other Events
9 Jan 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 199.84 k | 199.84 k | 199.84 k | 199.84 k | 199.84 k | 199.84 k |
Cash burn (monthly) | (no burn) | 1.00 mm | 257.80 k | 371.47 k | 357.28 k | 266.71 k |
Cash used (since last report) | n/a | 6.84 mm | 1.76 mm | 2.53 mm | 2.43 mm | 1.82 mm |
Cash remaining | n/a | -6.64 mm | -1.56 mm | -2.33 mm | -2.23 mm | -1.62 mm |
Runway (months of cash) | n/a | -6.6 | -6.0 | -6.3 | -6.3 | -6.1 |
Institutional ownership, Q2 2023
3.5% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 7 |
Opened positions | 1 |
Closed positions | 1 |
Increased positions | 1 |
Reduced positions | 1 |
13F shares | Current |
---|---|
Total value | 203.60 mm |
Total shares | 100.68 k |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Financial Advocates Investment Management | 57.51 k | $117.89 mm |
Geode Capital Management | 24.54 k | $49.82 mm |
STT State Street | 12.50 k | $25.38 mm |
Tower Research Capital | 4.83 k | $9.91 mm |
Reda Joseph | 1.00 k | $0.00 |
JPM JPMorgan Chase & Co. | 200.00 | $410.00 k |
Westside Investment Management | 94.00 | $193.00 k |
Proequities | 0.00 | $0.00 |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
5 Apr 24 | Weisblum Eric | Common Stock | Buy | Acquire P | No | No | 2.03 | 400 | 812.00 | 175,432 |
4 Apr 24 | Weisblum Eric | Common Stock | Buy | Acquire P | No | No | 1.96 | 600 | 1.18 k | 175,032 |
1 Apr 24 | Weisblum Eric | Common Stock | Buy | Acquire P | No | No | 1.91 | 1,100 | 2.10 k | 174,432 |
28 Mar 24 | Weisblum Eric | Common Stock | Buy | Acquire P | No | No | 1.94 | 3,408 | 6.61 k | 173,332 |
20 Dec 23 | Weisblum Eric | Common Stock | Buy | Acquire P | No | No | 1.61 | 200 | 322.00 | 169,924 |
19 Dec 23 | Weisblum Eric | Common Stock | Buy | Acquire P | No | No | 1.63 | 500 | 815.00 | 169,724 |
15 Dec 23 | Weisblum Eric | Common Stock | Buy | Acquire P | No | No | 1.52 | 900 | 1.37 k | 169,224 |
14 Dec 23 | Weisblum Eric | Common Stock | Buy | Acquire P | No | No | 1.5 | 200 | 300.00 | 168,324 |
7 Dec 23 | Weisblum Eric | Common Stock | Buy | Acquire P | No | No | 1.36 | 324 | 440.64 | 168,124 |
6 Dec 23 | Weisblum Eric | Common Stock | Buy | Acquire P | No | No | 1.34 | 76 | 101.84 | 167,800 |
News
Silo Pharma Announces Results For Intranasal PTSD Treatment
23 Apr 24
Psyched: DEA Revisits Ban On Two Psychedelics, Farewell Russell Newcombe, Podcast Episode On Kanna & More
17 Apr 24
12 Health Care Stocks Moving In Thursday's Pre-Market Session
11 Apr 24
Silo Pharma Set To Acquire Exclusive Licensing For Promising Alzheimer's Disease Therapeutic; SPC-14 Shows Cognitive And Stress Reduction Benefits In Preclinical Models
10 Apr 24
Citizens And 2 Other Stocks Under $3 Insiders Are Buying
9 Apr 24
Press releases
Silo Pharma Announces Positive Results for Intranasal PTSD Treatment
23 Apr 24
Silo Pharma set to Acquire Exclusive Licensing for Promising Alzheimer's Disease Therapeutic
10 Apr 24
Silo Pharma Exercises Option for Exclusive License Agreement for First-in-Class PTSD and Stress-Induced Anxiety Therapeutic
20 Mar 24
Silo Pharma Files Patent for Groundbreaking Ketamine Implant Therapeutic to Target Fibromyalgia and Chronic Pain
18 Mar 24
Silo Pharma Completes Successful Dose-Ranging Study of SPC-15 Intranasal Therapeutic for PTSD
28 Feb 24